Apricus Biosciences, Inc. 07.03.2013 14:00 --------------------------------------------------------------------------- SAN DIEGO, 2013-03-07 14:00 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) (www.apricusbio.com) announced today that Edward Cox, Vice President Corporate Development & Investor Relations, will present at the BIO-Europe Spring 2013 Partnering Conference, being held in Barcelona, Spain. Mr. Cox's presentation will take place on Wednesday, March 13, 2013 at 11:00 a.m. Local Time (6:00 a.m. Eastern Time). A replay of the presentation will be accessible to the public online at the Company's website at http://www.apricusbio.com. About Apricus Biosciences, Inc. Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros(r), for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories and Femprox(r), a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one 400-patient Phase III study in China. For further information on Apricus Bio, visit http://www.apricusbio.com. You can also receive information at http://twitter.com/apricusbio. CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 david@argotpartners.com News Source: NASDAQ OMX 07.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Apricus Biosciences, Inc. United States Phone: Fax: E-mail: Internet: ISIN: US9901429525 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences to Present at BIO-Europe Spring 2013
| Source: EQS Group AG